« Previous | Next » | All Messages |  CAMH Message Board Home | recommend post |  Ignore Poster

CAMH News Cambridge Heart to Present at the CIBC World Markets 17th Annual Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB-CAMH) announced today that its President and CEO, Mr. Jeff Langan, will present at the CIBC World Markets 17th Annual Healthcare Conference on Tuesday, November 7, 2006 at 12:40 PM EST. The conference is being held November 6 to 8 at the Waldorf-Astoria Hotel in New York City.

Mr. Langan will be discussing recent business developments. The presentation will be webcast and can be accessed on http://www.veracast.com/webcasts/cibcwm/healthcare06/32209438.cfm.

About Cambridge Heart

Cambridge Heart is engaged in the development and commercialization of products for the non-invasive diagnosis of cardiac disease, in particular addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company’s products incorporate its proprietary technology, Microvolt T-Wave Alternans, coupled with its patented Spectral Analytic Method and are the only diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The MTWA test is reimbursed by Medicare and major insurers in the USA, and is included in guidelines for cardiac care in the USA and Europe. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the OTCBB under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com

About the Cambridge Heart Microvolt T-Wave Alternans Test

The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person’s heartbeat called T-wave alternans. These tiny heartbeat variations – measured at one millionth of a volt – are detected in any clinical setting where titration of the heart rate is possible. The preparation for the test consists of placing proprietary sensors on a patient’s chest. Extensive clinical research has shown that patients with symptoms of, or who are at risk of, life threatening arrhythmias that test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death, while those who test negative are at minimal risk.